US Patent 7855226 Treatment of inflammatory bowel disease
Patent 7855226 was granted and assigned to Allergan, Inc. on December, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 31 Oct, 2023
Golden AI
Edits made to:
Article (+227 characters)
Article
Patent abstract
Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07855226 Treatment of inflammatory bowel disease US Patent 7855226 Treatment of inflammatory bowel disease
Infobox
Patent Number
0785522600
Patent Number
785522600
Edits on 25 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
078552260
Date of Patent
December 21, 2010
0Patent Application Number
110844540
Date Filed
March 17, 2005
0Official Website
Patent Primary Examiner
Edits on 6 Oct, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
078552260
Date of Patent
December 21, 2010
0Patent Application Number
110844540
Date Filed
March 17, 2005
0Official Website
Patent Primary Examiner
Edits on 4 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 6 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07855226 Treatment of inflammatory bowel disease
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07855226
Date of patent
December 21, 2010
Patent application number
11084454
Date Filed
March 17, 2005
Patent primary examiner
Find more entities like US Patent 7855226 Treatment of inflammatory bowel disease
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.